{"hq_id":"hq-c-mix-000083","name":"Candida auris","context":"human_adult","risk_level":"extreme","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"extreme","summary":"Candida auris is an emerging multidrug-resistant pathogenic yeast first described in Japan in 2009 (from an ear canal infection, hence 'auris'). Listed by CDC as an 'urgent threat' in the 2019 Antibiotic Resistance Threats Report — the highest threat category. C. auris is unique among Candida species in its ability to persist on environmental surfaces (hospital bed rails, IV poles, floors) for weeks and resist standard disinfection with quaternary ammonium compounds. Mortality: 30-60% in candidemia, though attributable mortality is difficult to determine as patients typically have severe comorbidities. Antifungal resistance: ~90% resistant to fluconazole; 30-40% resistant to amphotericin B; ~5% resistant to echinocandins; pan-resistant isolates (resistant to all three classes) have been documented. Frequently misidentified as C. haemulonii by standard laboratory methods — requires MALDI-TOF MS or molecular identification. Healthcare-associated outbreaks on 6 continents since 2009. Infection control: contact precautions, daily chlorhexidine bathing, environmental disinfection with chlorine-based products. WHO 2022 Fungal Priority Pathogens List: Critical priority (highest category).","source_refs":["aletheia_fungi_batch_2026"]},"meta":{"synthesis_version":"n/a","timestamp":"2026-07-28T05:17:44.539Z"},"_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult"]}